Full Text View
Tabular View
No Study Results Posted
Related Studies
Gemcitabine in Combination With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma
This study is ongoing, but not recruiting participants.
Study NCT01431794   Information provided by Sidney Kimmel Comprehensive Cancer Center

First Received on July 19, 2011.   Last Updated on May 3, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Additional conditions recognized in this trial
Adenocarcinoma
Adenocarcinoma, Mucinous
More general conditions related to this trial
Carcinoma
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Cystic, Mucinous, and Serous
Neoplasms, Glandular and Epithelial
Interventions listed in this trial
LDE-225
Gemcitabine
More general drug interventions related to this trial
Anti-Infective Agents
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antiviral Agents
Enzyme Inhibitors
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Radiation-Sensitizing Agents
Therapeutic Uses
Sponsors listed in this trial
Sidney Kimmel Comprehensive Cancer Center
Novartis


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services